Drug class
Tyrosine Kinase Inhibitors clinical trials
A class of medicines: the studies that test any of its 480 members, each study once. Members are as MeSH files each medicine’s actions, and as the NCI Thesaurus classes newer ones.
Keep track of what changes. Save the tyrosine kinase inhibitors studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesMedicines in this class
Studies that test each. A study of two counts under both, and once above.
And 440 more, each tested in fewer studies.
Studies by the year they started
10,696 studies that test it; most in 2021 (697); 24 more planned to start later
| Year | Studies |
|---|---|
| 1993 | 1 |
| 1997 | 1 |
| 1998 | 2 |
| 1999 | 6 |
| 2000 | 29 |
| 2001 | 55 |
| 2002 | 112 |
| 2003 | 127 |
| 2004 | 206 |
| 2005 | 259 |
| 2006 | 338 |
| 2007 | 425 |
| 2008 | 431 |
| 2009 | 413 |
| 2010 | 333 |
| 2011 | 375 |
| 2012 | 376 |
| 2013 | 360 |
| 2014 | 377 |
| 2015 | 418 |
| 2016 | 468 |
| 2017 | 453 |
| 2018 | 505 |
| 2019 | 609 |
| 2020 | 648 |
| 2021 | 697 |
| 2022 | 601 |
| 2023 | 548 |
| 2024 | 547 |
| 2025 | 490 |
| 2026 | 486 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4,451 · Other 6,292
National Cancer Institute (NCI) (512) · Pfizer (373) · M.D. Anderson Cancer Center (319) · Novartis Pharmaceuticals (282) · AstraZeneca (210) · Bristol-Myers Squibb (174) · Boehringer Ingelheim (141) · Incyte Corporation (135)
Studies
Open first, then newest update. How each study uses a medicine is read from its arms, and is right about nine times in ten.
Testing one of them · 10,743
- Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase Inhibitor or Pirtobrutinib and Previously Treated With a BCL2 InhibitorNot yet recruitingPhase 2National Heart, Lung, and Blood Institute (NHLBI)NCT07796373Written as Nemtabrutinib
- Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast CancerNot yet recruitingPhase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07892274Written as Pyrotinib
- Ceritinib Treatment for Recurrent MeningiomasNot yet recruitingPhase 2Kevin PetreccaNCT07893197Written as Ceritinib
- A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian CancerRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06394804Written as Defactinib
- A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)RecruitingPhase 2National Cancer Institute (NCI)NCT06124157Written as Dasatinib
- Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 TrialRecruitingPhase 2Fred Hutchinson Cancer CenterNCT04941716Written as Acalabrutinib
- ctDNA-Guided Sunitinib And Regorafenib Therapy for GISTRecruitingPhase 2University of MiamiNCT05366816Written as Sunitinib
- Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia AreataRecruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT05398809Written as Ruxolitinib
- Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World ContextRecruitingNot applicablePfizerNCT06487078Written as Lorlatinib
- Study of Ruxolitinib in Relapsed or Refractory T or NK Cell LymphomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT02974647Written as Ruxolitinib
- Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine TumorsRecruitingPhase 2/3ExelixisNCT06943755Written as Zanzalintinib
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT05564390Written as Gilteritinib
- A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GlioblastomaRecruitingPhase 2/3Global Coalition for Adaptive ResearchNCT03970447Written as Regorafenib
- Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative NeoplasmsRecruitingPhase 1/2National Cancer Institute (NCI)NCT06303193Written as pacritinib
- Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific AntibodiesRecruitingPhase 1National Heart, Lung, and Blood Institute (NHLBI)NCT06948097Written as fostamatinib
- MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without ObinutuzumabRecruitingPhase 2AstraZenecaNCT07024706Written as Acalabrutinib
- Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver CancerRecruitingPhase 1/2Devalingam MahalingamNCT07042919Written as Zanzalintinib
- Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)RecruitingPhase 2University of Texas Southwestern Medical CenterNCT05931393Written as Cabozantinib 80 MG
- Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)RecruitingPhase 1/2Dizal PharmaceuticalsNCT07079475Written as DZD6008
- A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)RecruitingPhase 1Astellas Pharma Global Development, Inc.NCT07140016Written as gilteritinib
See all 10,743 studies that test one of the tyrosine kinase inhibitors →
Codes
What other systems call Tyrosine Kinase Inhibitors · ClinicalTrials.gg INT006863
- MeSH (NLM) D000092004Tyrosine Kinase InhibitorsOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000092004 | Tyrosine Kinase Inhibitors | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.